2025 Guidelines for direct oral anticoagulants: a practical guidance on the prescription, laboratory testing, peri‐operative and bleeding management
Internal Medicine Journal · 2025-07 · 55 (7) · 1174-1183
DOI: 10.1111/imj.70103 ↗Kurz gefasst
Leitlinie in der Zeitschrift Internal Medicine Journal, online erschienen am 31.05.2025. Verfasst von Huyen A Tran und 7 weiteren Autor:innen. Beteiligte Einrichtung: Haemostasis Thrombosis Unit, The Alfred Hospital, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Anticoagulants, Hemorrhage, Perioperative Care. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Direct oral anticoagulants (DOACs) are widely prescribed to prevent and treat venous and arterial thromboembolism, supported by published evidence, and are preferred over warfarin in many guidelines. Although the risk of major bleeding, in particular intracranial haemorrhage (ICH), is decreased with DOACs, gastrointestinal bleeding is increased with some DOACs, and the case fatality rate of bleeding remains high. Therefore, it is important to (i) prescribe DOACs appropriately, (ii) have strategies to manage major bleeding including the use of specific reversal agents and (iii) interrupt and resume DOACs for procedures. The main recommendations are as follows: (i) Select the appropriate dose of DOAC according to indications and consider patient factors to minimise bleeding risks; (ii) DOACs do not require routine laboratory testing; (iii) for life‐threatening uncontrollable bleeding, specific agents can be used to reverse the anticoagulant effects of DOACs; and (iv) DOACs can be interrupted for planned procedures without the need for ‘bridging’ with low‐molecular‐weight heparin (LMWH). The anticoagulant effects of DOACs can be reversed with specific agents, such as andexanet for apixaban and rivaroxaban and idarucizumab for dabigatran. If not available, pro‐haemostatic agents such as prothrombin complex concentrates or activated prothrombin complex concentrates can be considered. DOACs can be interrupted and resumed for procedures without the need for ‘bridging’ with LMWH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Haemostasis Thrombosis Unit, The Alfred Hospital, Melbourne, Victoria, Australia.
- Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia.
- Haematology Department, Royal North Shore Hospital, Auckland, New Zealand.
- Haematology Department, Perth Blood Institute, Perth, Western Australia, Australia.
- Haematology Department, Westmead Hospital, Sydney, New South Wales, Australia.
- Haematology Department, Auckland City Hospital, Auckland, New Zealand.
ORCID-Profile: Huyen A Tran, Eileen Merriman
Zitieren
APA
Tran, H. A., Merriman, E., Baker, R., Curnow, J., Young, L., Tan, C. W., McRae, S., & Chunilal, S. D. (2025). 2025 Guidelines for direct oral anticoagulants: a practical guidance on the prescription, laboratory testing, peri‐operative and bleeding management. Internal Medicine Journal, 55(7), 1174-1183. https://doi.org/10.1111/imj.70103
Vancouver
Tran HA, Merriman E, Baker R, Curnow J, Young L, Tan CW, et al. 2025 Guidelines for direct oral anticoagulants: a practical guidance on the prescription, laboratory testing, peri‐operative and bleeding management. Internal Medicine Journal. 2025;55(7):1174-1183. doi:10.1111/imj.70103
BibTeX
@article{Tran2025,
author = {Tran, Huyen A and Merriman, Eileen and Baker, Ross and Curnow, Jennifer and Young, Laura and Tan, Chee Wee and McRae, Simon and Chunilal, Sanjeev D},
title = {2025 Guidelines for direct oral anticoagulants: a practical guidance on the prescription, laboratory testing, peri‐operative and bleeding management},
journal = {Internal Medicine Journal},
year = {2025},
volume = {55},
number = {7},
pages = {1174--1183},
doi = {10.1111/imj.70103}
}
EUVIMED